Russian Prime Minister Signs Decree on Tobacco Product Marking Expansion

Regulations by 2FIRSTS.ai
Mar.08.2024
Russian Prime Minister Signs Decree on Tobacco Product Marking Expansion
Russian Prime Minister Mikhail Mishustin has signed a decree expanding the scope of tobacco product labeling, aimed at reducing illegal production.

According to Russian media outlet Lenta, Russian Prime Minister Mikhail Mishustin has signed a decree to expand the scope of labeling for tobacco products. Under this decree, all raw materials used in the production of tobacco and nicotine-containing products must be labeled.

 

This resolution is a part of efforts to reduce the illegal production of tobacco and other nicotine-containing products. It is reported that most of the provisions of this resolution will take effect within 30 days, with some provisions, such as the refusal to issue identification codes, taking effect on July 1st.

 

In 2019, Russia began implementing digital marking on tobacco products, and starting from February 1, 2022, fines will be imposed on individuals carrying unmarked tobacco products exceeding 200 cigarettes or 50 cigars. By October 2023, the regulations will extend to unmarked e-cigarettes and the transportation of e-cigarettes.

 

According to Ekaterina Priyezheva, Deputy Minister of Industry and Trade of Russia, over the past three years, cracking down on the illegal trafficking of tobacco products through labeling has generated an additional 245 billion rubles (approximately 2.7 billion US dollars) in revenue for the country.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
UK Vape Distributor JM Wholesale Files Notice to Enter Administration
UK Vape Distributor JM Wholesale Files Notice to Enter Administration
UK vape distributor JM Wholesale filed a notice on March 20 to enter administration. The Leicestershire-based company submitted the notice through Shakespeare Martineau, with Quantuma expected to be appointed as administrator.
Mar.23 by 2FIRSTS.ai
Japan to Raise Heated Tobacco Prices From April; BAT Japan Keeps Prices Unchanged for 38 glo Tobacco Stick Products
Japan to Raise Heated Tobacco Prices From April; BAT Japan Keeps Prices Unchanged for 38 glo Tobacco Stick Products
Japan will implement price increases centered on heated tobacco products from April 1, 2026, following a tobacco tax hike. BAT Japan has decided to keep current prices unchanged for 38 glo-compatible tobacco stick products across the Velo, neo, Lucky Strike, and Kent lines.
Mar.30 by 2FIRSTS.ai
Canadian Conservative MP’s Promotion of Zyn Draws Opposition From Local Nicotine Pouch Brand
Canadian Conservative MP’s Promotion of Zyn Draws Opposition From Local Nicotine Pouch Brand
Conservative MP Jamil Jivani’s public support for nicotine pouch brand Zyn has drawn attention on Canadian university campuses, but Imperial Tobacco, which makes the only similar Canadian product, Zonnic, said it does not support the promotion of an unauthorized competitor.
Mar.18 by 2FIRSTS.ai
Poland Weighs Ban on Disposable Vapes, Tightens Rules on Nicotine Pouches
Poland Weighs Ban on Disposable Vapes, Tightens Rules on Nicotine Pouches
Poland plans to amend its tobacco control legislation, proposing a ban on disposable e-cigarettes (both nicotine-containing and nicotine-free) while simultaneously tightening regulations on nicotine pouches and other novel nicotine products. Nicotine pouches may be permitted only in "tobacco flavour" variants to reduce their appeal to young people.
Mar.10 by 2FIRSTS.ai
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai